Showing 40,021 - 40,040 results of 65,337 for search '(( 5 mg decrease ) OR ( 5 ((((mean decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.02s Refine Results
  1. 40021

    Presentation_1_Molecular Characterization and Expression of Cytochrome P450 Aromatase in Atlantic Croaker Brain: Regulation by Antioxidant Status and Nitric Oxide Synthase During H... by Md Saydur Rahman (9291165)

    Published 2021
    “…Hypothalamic AROM activity and mRNA levels were also decreased by pharmacological treatment with N-ethylmaleimide (NEM, an alkylating drug that modifies sulfhydryl groups) of fish exposed to normoxic (DO: ∼6.5 mg/L) conditions. …”
  2. 40022

    Data Sheet 7_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  3. 40023

    Data Sheet 8_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  4. 40024

    Data Sheet 4_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  5. 40025

    Data Sheet 9_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  6. 40026

    Data Sheet 6_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  7. 40027

    Image 1_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo.jpeg... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  8. 40028

    Data Sheet 2_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  9. 40029

    Data Sheet 1_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  10. 40030

    Data Sheet 3_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo... by Xirui Xia (12075476)

    Published 2024
    “…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
  11. 40031

    Cordycepin prevents the esophageal stricture formation in the alkali-burn rat model by exerting anti-inflammatory and antifibrotic effects by Gulcin Ercan (5223101)

    Published 2021
    “…Methods Caustic esophageal burn was introduced by 37.5% of NaOH to distal esophagus. Thirty-two Wistar albino rats were divided in four groups: sham rats undergone laparotomy, treated with 0.9% NaCl; control rats injured with NaOH without cordycepin treatment; cordycepin group injured with NaOH, treated with 20 mg/kg cordycepin; prednisolone group injured with NaOH, treated with 1 mg/kg prednisolone for 28 days. …”
  12. 40032

    Image 1_Regulation effect of seed priming on sowing rate of direct seeding of rice under salt stress.pdf by Yicheng Zhang (790286)

    Published 2025
    “…<p>Direct seeding of rice (DSR) is a widely used method for its labor- and cost-saving advantages. …”
  13. 40033

    Table 1_Regulation effect of seed priming on sowing rate of direct seeding of rice under salt stress.pdf by Yicheng Zhang (790286)

    Published 2025
    “…<p>Direct seeding of rice (DSR) is a widely used method for its labor- and cost-saving advantages. …”
  14. 40034

    FIGURE 6 from Targeting <i>MALAT1</i> Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer by Anjali Yadav (17117308)

    Published 2023
    “…The experiments were performed with <i>n</i> = 3 biologically independent samples; the data represents mean ± SEM. Extra sums of the square F-test was used to compute the statistical significance and compare the curves in A. …”
  15. 40035

    CaMKII regulates the number of DCVs entering the axon but not their trafficking properties. by Alessandro Moro (2623396)

    Published 2020
    “…<p>(A) Schematic representation of AIS targeting; Na<sub>v</sub>II-III BFP was used to visualize the region of the AIS. …”
  16. 40036

    Table_1_The effects of blurred visual inputs with different levels on the cerebral activity during free level walking.docx by Mingxin Ao (679210)

    Published 2023
    “…The cautious gait pattern, characterized by a decrease in gait speed (p < 0.001), a greater amplitude of deviation from the right ahead (p < 0.001), a prolonged stance time (p = 0.001), a restricted range of motion in the hip on the right side (p ≤ 0.010), and an increased knee flexion during stance on the left side (p = 0.014), was only detected at the status of V0. …”
  17. 40037
  18. 40038
  19. 40039
  20. 40040